SCHEMBL3364006

SCHEMBL3364006

CN(C(=O)CC#N)C1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.43
JAK3 P52333 3/20 0.42
JAK2 O60674 2/20 0.42
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PKM P14618 1/20 0.40
NPBWR1 P48145 1/20 0.40
FAAH O00519 1/20 0.40
PHGDH O43175 1/20 0.40
MGLL Q99685 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
CASP7 P55210 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
CASP1 P29466 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19431720 0.82 JAK3 (0.37) ALDH1A1LMNATSHRJAK3JAK2
SCHEMBL11816062 0.81 KMT2A (0.40) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL10723835 0.78 ALDH1A1 (0.59) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL7129642 0.78 ALDH1A1 (0.59) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL5143781 0.76 ALDH1A1 (0.58) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL6608940 0.76 ALDH1A1 (0.58) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL5143783 0.76 ALDH1A1 (0.58) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL11284398 0.75 ALDH1A1 (0.56) ALDH1A1LMNATSHRKMT2AMEN1
SCHEMBL10722325 0.75 ALDH1A1 (0.56) ALDH1A1TSHRKMT2AMEN1NPSR1
SCHEMBL10453317 0.75 ALDH1A1 (0.56) ALDH1A1TSHRKMT2AMEN1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436006-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-05-07 US disclosed
US-8426429-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-04-23 US disclosed
US-8383637-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-02-26 US disclosed
EP-1776349-B1 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA NV (BE) 2010-10-06 EP disclosed
US-20060178383-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-10 US disclosed
US-20060079686-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA NV (BE) 2006-04-13 US disclosed
US-20060079687-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178383-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP ALDH1A1 2650/4885LMNA 2653/4885TSHR 4868/4885
US-20060079687-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP ALDH1A1 2650/4885LMNA 2653/4885TSHR 4868/4885
US-20060079686-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP ALDH1A1 2650/4885LMNA 2653/4885TSHR 4868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.